These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 30144292)

  • 1. Combined hydroxyurea and ET
    Taylor C; Kasztan M; Tao B; Pollock JS; Pollock DM
    Acta Physiol (Oxf); 2019 Feb; 225(2):e13178. PubMed ID: 30144292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Endothelin-A Receptor Antagonism Provides Robust Renal Protection in Humanized Sickle Cell Disease Mice.
    Kasztan M; Fox BM; Speed JS; De Miguel C; Gohar EY; Townes TM; Kutlar A; Pollock JS; Pollock DM
    J Am Soc Nephrol; 2017 Aug; 28(8):2443-2458. PubMed ID: 28348063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydroxyurea improves nitric oxide bioavailability in humanized sickle cell mice.
    Taylor CM; Kasztan M; Sedaka R; Molina PA; Dunaway LS; Pollock JS; Pollock DM
    Am J Physiol Regul Integr Comp Physiol; 2021 May; 320(5):R630-R640. PubMed ID: 33624556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of ET-1 and sex in glomerular hyperfiltration in humanized sickle cell mice.
    Kasztan M; Pollock DM
    Clin Sci (Lond); 2019 Jul; 133(13):1475-1486. PubMed ID: 31273050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse effects of a clinically relevant dose of hydroxyurea used for the treatment of sickle cell disease on male fertility endpoints.
    Jones KM; Niaz MS; Brooks CM; Roberson SI; Aguinaga MP; Hills ER; Rice VM; Bourne P; Bruce D; Archibong AE
    Int J Environ Res Public Health; 2009 Mar; 6(3):1124-44. PubMed ID: 19440437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of hydroxyurea therapy on intravascular hemolysis and endothelial dysfunction markers in sickle cell anemia patients.
    Chenou F; Hounkpe BW; Domingos IF; Tonassé WV; Batista THC; Santana RM; Arcanjo GDS; Alagbe AE; Araújo ADS; Lucena-Araújo AR; Bezerra MAC; Costa FF; Sonati MF; De Paula EV; Dos Santos MNN
    Ann Hematol; 2021 Nov; 100(11):2669-2676. PubMed ID: 34453189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
    Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia.
    Di Maggio R; Hsieh MM; Zhao X; Calvaruso G; Rigano P; Renda D; Tisdale JF; Maggio A
    Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease.
    el-Hazmi MA; al-Momen A; Kandaswamy S; Huraib S; Harakati M; al-Mohareb F; Warsy AS
    Acta Haematol; 1995; 94(3):128-34. PubMed ID: 7502628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydroxyurea (hydroxycarbamide) genotoxicity in pediatric patients with sickle cell disease.
    Rodriguez A; Duez P; Dedeken L; Cotton F; Ferster A
    Pediatr Blood Cancer; 2018 Jul; 65(7):e27022. PubMed ID: 29512872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of erythrocyte arginase activity in sickle cell disease patients during hydroxyurea therapy.
    Iyamu EW; Cecil R; Parkin L; Woods G; Ohene-Frempong K; Asakura T
    Br J Haematol; 2005 Nov; 131(3):389-94. PubMed ID: 16225659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endothelin-1 contributes to the progression of renal injury in sickle cell disease via reactive oxygen species.
    Heimlich JB; Speed JS; O'Connor PM; Pollock JS; Townes TM; Meiler SE; Kutlar A; Pollock DM
    Br J Pharmacol; 2016 Jan; 173(2):386-95. PubMed ID: 26561980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perception to hydroxyurea therapy in patients with sickle cell disease: Report from 3 centers.
    Korubo KI; Onodingene NM; Okoye HC; Omunakwe HE
    Ann Afr Med; 2021; 20(2):127-131. PubMed ID: 34213480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble Fas/FasL ratio as a marker of vasculopathy in children and adolescents with sickle cell disease.
    Adly AA; Ismail EA; Andrawes NG; Mahmoud MM; Eladawy R
    Cytokine; 2016 Mar; 79():52-8. PubMed ID: 26765484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydroxyurea treatment and neurocognitive functioning in sickle cell disease from school age to young adulthood.
    Heitzer AM; Longoria J; Okhomina V; Wang WC; Raches D; Potter B; Jacola LM; Porter J; Schreiber JE; King AA; Kang G; Hankins JS
    Br J Haematol; 2021 Oct; 195(2):256-266. PubMed ID: 34272726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Higher nocturnal and awake oxygen saturations in children with sickle cell disease receiving hydroxyurea therapy.
    Narang I; Kadmon G; Lai D; Dhanju S; Kirby-Allen M; Odame I; Amin R; Lu Z; Al-Saleh S
    Ann Am Thorac Soc; 2015 Jul; 12(7):1044-9. PubMed ID: 25970812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in urine albumin to creatinine ratio with the initiation of hydroxyurea therapy among children and adolescents with sickle cell disease.
    Tehseen S; Joiner CH; Lane PA; Yee ME
    Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28612449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study protocol for a randomized controlled trial to assess the feasibility of an open label intervention to improve hydroxyurea adherence in youth with sickle cell disease.
    Smaldone A; Findley S; Bakken S; Matiz LA; Rosenthal SL; Jia H; Matos S; Manwani D; Green NS
    Contemp Clin Trials; 2016 Jul; 49():134-42. PubMed ID: 27327779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxyurea therapy in sickle cell anemia patients aids to maintain oral fungal colonization balance.
    Salvia AC; Figueiredo MS; Braga JA; Pereira DF; Brighenti FL; Koga-Ito CY
    J Oral Pathol Med; 2013 Aug; 42(7):570-5. PubMed ID: 23278631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher oxygen saturation with hydroxyurea in paediatric sickle cell disease.
    van Geyzel L; Arigliani M; Inusa B; Singh B; Kozlowska W; Chakravorty S; Bossley CJ; Ruiz G; Rees D; Gupta A
    Arch Dis Child; 2020 Jun; 105(6):575-579. PubMed ID: 31871045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.